4.6 Review

The history of matrix metalloproteinases: milestones, myths, and misperceptions

Journal

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpheart.00577.2012

Keywords

review; matrix metalloproteinases; MMP; cardiovascular disease; myocardial infarction

Funding

  1. Multiple Sclerosis National Research Institute
  2. NHLBI HHSN [268201000036C (N01-HV-00244)]
  3. Max and Minnie Tomerlin Voelcker Fund
  4. Veteran's Administration (Merit)
  5. Novartis
  6. Amylin Pharmaceuticals, Inc.
  7. Canopus Corporation
  8. [R01-CA-098799]
  9. [R01-HL-075360]

Ask authors/readers for more resources

Iyer RP, Patterson NL, Fields GB, Lindsey ML. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol 303: H919-H930, 2012. First published August 17, 2012; doi:10.1152/ajpheart.00577.2012.-Since the discovery of tadpole collagenase in 1962, the matrix metalloproteinase (MMP) family has emerged as a significant proteinase group with recognized effects on the cardiovascular system. Over the last 40 years, many milestones have been achieved, from the identification of the first MMP, to the generation of the first MMP cDNA clone and null mouse, to the clinical approval of the first MMP inhibitor. Over the years, a few myths and misunderstandings have interwoven into the truths. In this review, we will discuss the major milestones of MMP research, as well as review the misinterpretations and misperceptions that have evolved. Clarifying the confusions and dispelling the myths will both provide a better understanding of MMP properties and functions and focus the cardiovascular field on the outstanding research questions that need to be addressed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available